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Abstract
Introduction: The increasing number of reports on the relation between transfusion of stored red blood cells
(RBCs) and adverse patient outcome has sparked an intense debate on the benefits and risks of blood transfusions.
Meanwhile, the pathophysiological mechanisms underlying this postulated relation remain unclear. The
development of hemolysis during storage might contribute to this mechanism by release of free hemoglobin
(fHb), a potent nitric oxide (NO) scavenger, which may impair vasodilation and microcirculatory perfusion after
transfusion. The objective of this prospective observational pilot study was to establish whether RBC transfusion
results in increased circulating fHb levels and plasma NO consumption. In addition, the relation between increased
fHb values and circulating haptoglobin, its natural scavenger, was studied.
Methods: Thirty patients electively received 1 stored packed RBC unit (n = 8) or 2 stored packed RBC units (n =
22). Blood samples were drawn to analyze plasma levels of fHb, haptoglobin, and NO consumption prior to
transfusion, and 15, 30, 60 and 120 minutes and 24 hours after transfusion. Differences were compared using
Pearson’s chi-square test or Fisher’s exact test for dichotomous variables, or an independent-sample t test or Mann-
Whitney U test for continuous data. Continuous, multiple-timepoint data were analyzed using repeated one-way
analysis of variance or the Kruskall-Wallis test. Correlations were analyzed using Spearman or Pearson correlation.
Results: Storage duration correlated significantly with fHb concentrations and NO consumption within the storage
medium (r = 0.51, P < 0.001 and r = 0.62, P = 0.002). fHb also significantly correlated with NO consumption directly
(r = 0.61, P = 0.002). Transfusion of 2 RBC units significantly increased circulating fHb and NO consumption in the
recipient (P < 0.001 and P < 0.05, respectively), in contrast to transfusion of 1 stored RBC unit. Storage duration of
the blood products did not correlate with changes in fHb and NO consumption in the recipient. In contrast, pre-
transfusion recipient plasma haptoglobin levels inversely influenced post-transfusion fHb concentrations.
Conclusion: These data suggest that RBC transfusion can significantly increase post-transfusion plasma fHb levels
and plasma NO consumption in the recipient. This finding may contribute to the potential pathophysiological
mechanism underlying the much-discussed adverse relation between blood transfusions and patient outcome. This
observation may be of particular importance for patients with substantial transfusion requirements.
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Introduction
Transfusion of stored red blood cells (RBCs) is a common
medical procedure, particularly in the context of critical
care [1]. Approximately 40% of patients admitted to the
ICU receive packed red blood cell (pRBC) transfusion,
with a mean of 5 units per patient [2]. The rationale of
pRBC administration is enhancement of intravascular
oxygen-carrying capacity and thus improvement of tissue
oxygenation. However, recent insights into pathological
changes of RBC functionality and integrity during storage
- collectively known as the storage lesion - has drawn
attention to the potential negative consequences of pRBC
transfusion as it limits the post-transfusion survival of
RBCs in vivo [3]. The storage lesion includes decreased
RBC viability and deformability, increased RBC aggregabil-
ity and adhesiveness, enhanced susceptibility to oxidative
damage, formation of membrane vesicles resulting in loss
of surface area, and increased cell density [3-5]. Further-
more, several changes to the RBC microenvironment (the
storage medium) have been reported; a decrease in pH;
accumulation of proinflammatory substances, hemoglo-
bin-derived free iron, and microvesicles containing large
amounts of free hemoglobin (fHb) [6]; and increased levels
of hemolysis markers such as potassium, arginase-1, and
fHb in the storage medium [3,7-9]. Generally, increasing
storage duration aggravates the storage lesion [3].
The profound beneficial effects of transfusion cannot be
understated. Nevertheless, the number of studies reporting
on the potential adverse effects of (massive) pRBC transfu-
sion on patient morbidity and mortality has increased sig-
nificantly in recent years, which has initiated an intense
debate on the benefits and risks of pRBC, particularly
focusing on the effects of younger versus older pRBCs
[10-15]. Although the exact mechanisms underlying the
adverse effects of pRBC administration have not yet been
fully elucidated, the release of fHb and its influence on the
intravascular nitric oxide (NO) metabolism after transfu-
sion has been attributed an important role [6]. fHb was
found to be a potent scavenger of NO, the most important
endogenous vasodilator [16]. In line with this finding,
increased fHb levels in patients with chronic and acute
hemolysis have been associated with decreased NO bioa-
vailability within the microcapillary bed, decreased organ
perfusion and increased organ injury [16-18]. Similarly,
transfusion of stored pRBC units may enhance fHb con-
centrations in patients after transfusion - for instance, as a
consequence of premature intravascular rupture of the
transfused erythrocytes, or due to the transfusion of the
fHb-containing storage medium [8]. In line with this
hypothesis, it was recently shown that transfusion of fHb-
containing supernatant of stored erythrocytes in rats
caused a significant increase in blood pressure that corre-
lated with the fHb levels in the supernatant [6].
This prospective observation pilot study aimed to
investigate whether transfusion of 1 or 2 pRBC units can
result in enhanced circulating fHb levels and plasma NO
consumption in the recipient. In addition, we studied
whether the pRBC storage duration or pre-transfusion
levels of plasma haptoglobin (Hp) - the physiological fHb
scavenger - influenced the change of plasma fHb in the
recipient after transfusion.
Materials and methods
Patients
Based on previous experiments, we calculated that inclu-
sion of 22 patients would provide sufficient power (0.80
with a = 0.05) to detect significant increases in plasma
fHb levels in the recipient after transfusion of 2 stored
pRBC units. To compare patients receiving 1 versus 2
stored RBC units, all patients screened during the inclu-
sion period receiving only 1 pRBC unit were also included.
To that end, 58 patients admitted to the Department of
Hematology and Oncology of the Maastricht University
Medical Center between 1 May 2010 and 1 November
2010 were screened for eligibility for study participation
using predetermined inclusion and exclusion criteria. This
resulted in the inclusion of 22 patients undergoing trans-
fusion with 2 pRBC units, and eight patients undergoing
transfusion with 1 pRBC unit. All patients provided writ-
ten informed consent at least 24 hours before transfusion.
The study protocol was approved by the Ethical Review
Board of the Maastricht University Medical Center in
accordance with the Declaration of Helsinki (amended in
Seoul, 2008).
We only included adult patients (≥ 18 years) with nor-
mal kidney function and normal liver function, who were
in a stable clinical phase of their disease. The rationale of
choosing patients with a (hematological) malignancy was
that these patients frequently need blood transfusions.
Furthermore, these patients generally have a central
venous line (in the jugular or subclavian vein) enabling
nontraumatic blood sampling, and thus minimizing sam-
pling-induced hemolysis. Absence of such a central venous
line was a reason for exclusion. Other inclusion criteria
were normal kidney function defined as an estimated glo-
merular filtration rate of 60 ml/minute/1.73 m2 or higher,
assessed by the abbreviated Modification of Diet in Renal
Disease recommended by the National Kidney Foundation
[19]. Normal liver function was indicated by normal pre-
transfusion bilirubin levels. Furthermore, presence of a
central venous line (in the jugular or subclavian vein) was
mandatory to enable nontraumatic blood sampling, thus
minimizing sampling-induced hemolysis.
C-reactive protein levels exceeding 10 mg/l were a
reason for patient exclusion since an active inflamma-
tory process may lead to increased Hp levels. Hp is the
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physiological fHb scavenger, so patients with increased
Hp concentrations may be able to clear fHb more read-
ily compared with patients with normal plasma Hp
levels (0.25 to 1.9 g/l). Because Hp is not routinely mea-
sured in patients prior to blood transfusion at our hos-
pital, we were not able to use Hp concentrations
directly to include or exclude patients. Other exclusion
criteria included pre-existent hemolytic disease, and
transfusion of pRBCs within 72 hours prior to inclusion.
We chose a timeframe of 72 hours on the basis of pre-
vious (unpublished) data showing that, even after strong
increases of plasma fHb, these levels are back to normal
values at 24 hours after peak fHb levels were observed
(in a stable clinical condition without ongoing hemoly-
sis). The investigators did not have any influence on the
selection of the transfused pRBCs with regard to storage
duration or any other parameter.
Red blood cell products
All transfused pRBCs were collected and prepared for
transfusion by the Sanquin Blood Supply Foundation, the
Netherlands. The maximum storage duration of pRBC
units allowed in the Netherlands after the collection date
is 35 days. All pRBC units were pre-storage leucodepleted,
according to the standard protocol. The storage solution
consisted of a mixture of saline, adenine, glucose and
mannitol. The mean volume and hematocrit level of the
transfused pRBC units were 275 ml and 0.60, respectively.
The pRBCs were subsequently distributed to and stored
by the Central Diagnostic Laboratory of the Maastricht
University Medical Center until use. In cases where 2
pRBC units were administered, the storage duration of
both pRBC units was never more than 2 days apart.
The transfusion protocol used at our institution was
the nationally used transfusion protocol as defined by the
Dutch Institute for Healthcare Improvement CBO (Cen-
tral Accompaniment Organization). In short, patients
and donors are matched based on blood type (A, B, AB,
and O) and rhesus D phenotype. Patients and donor
blood were also matched according to the presence of
irregular antibodies (or autoantibodies). In women under
the age of 45, donor blood was always Kell-negative. The
majority of transfused pRBCs were of blood type O (n =
32, 61.5%) and were Rh-negative (n = 33, 63.5%). The
remainder of pRBC units were either of blood type A
(n = 16, 30.8%) or blood type B (n = 4, 7.7%). Eight
patients were transfused with irradiated (25 Gy) pRBCs.
Each pRBC unit was administered in a 60-minute to 90-
minute timeframe. None of the patients received fresh
frozen plasma or platelets during the study period.
Blood sampling and sample processing
Central venous blood was drawn from the venous line
by an experienced nurse at six preset time points; pre-
transfusion (blood sample taken on the morning of
transfusion in the context of routine patient care), 15
minutes after transfusion (T15) of all pRBCs (1 or 2
units), 30 minutes after transfusion (T30), 60 minutes
after transfusion (T60), 120 minutes after transfusion
(T120), and the morning after transfusion (T24). Prior
to every sample collection, the central venous line was
flushed with sterile saline to prevent sampling of the
previously administered pRBCs (which was given via the
same line) or remnants of the previously collected blood
sample. Whole blood was gently collected using sterile
syringes, instead of standard blood collection tubes
(vacutainers), to prevent vacuum-induced hemolysis.
After collection of two syringes, the blood from the sec-
ond syringe (not contaminated with sterile saline) was
immediately transferred to an ethylenediamine-tetraace-
tic acid-containing blood collection tube without
vacuum (Becton Dickinson, Franklin Lakes, NJ, USA),
carefully mixed by gentle rotation, and subsequently
stored for a maximum of 1 hour at 4°C until further
processing. After centrifugation (1,500 × g at 4°C for 15
minutes without braking), plasma was aliquoted and
stored at -20°C until further analysis.
Laboratory analysis
Free hemoglobin
The fHb concentrations, indicating hemolysis, were mea-
sured in all patient plasma samples (n = 30) and in the
storage medium of every administered pRBC (n = 52).
fHb was analyzed by derivative spectrometry as described
in more detail elsewhere [20]. The detection limit of this
assay was 2 μmol/l.
Haptoglobin
Plasma Hp concentrations of all patient samples and Hp
levels in the storage medium of all transfused pRBC were
measured on a validated Beckman LX20 clinical chemistry
analyzer (Beckman Coulter, Brea, CA, USA) via a turbidi-
metric method by the Laboratory of Hematology of the
Maastricht University Medical Center.
Nitric oxide consumption assay
To evaluate whether increased fHb levels influenced the
NO-consuming capacity of plasma after transfusion, we
analyzed the NO consumption in all plasma samples of 13
randomly selected patients from our total patient group of
30 (40%; four patients transfused with 1 pRBC unit, nine
patients transfused with 2 pRBC units), and in the storage
medium of the 22 pRBC units administered to these
patients. Random selection of patients was carried out
using SPSS software (SPSS Inc., Chicago, IL, USA). Unfor-
tunately, we were not able to analyze every sample from
the total patient group due to time and cost constraints.
The complete protocol of the NO consumption assay is
described in more detail elsewhere [16,21]. In short, a
40 μM solution of the NO donor (DETA NONOate;
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Cayman Chemical, Ann Harbor, MI, USA) was prepared
in PBS (pH 7.4) in a glass vessel purged with nitrogen in
line with a NO chemiluminescence analyzer (Sievers
Model 280i; GE, Boulder, CO, USA). The subsequent
decay of DETA NONOate, releasing NO, produced a
steady-state NO signal of about 50 to 70 mV. When the
signal became stable, 50 μl plasma samples or standards
were injected into the DETA NONOate solution, decreas-
ing the NO signal in cases of NO consumption. Data were
transferred to the software program ORIGIN Version 6.1
(OriginLab, Northampton, MA, USA) for analysis of the
area under the curve of decreasing NO signal over time.
The amount of NO consumption by plasma is quantified
by comparison of the area under the curve with that of
NO gas standards (produced from injections of nitrite into
tri-iodide).
Statistical analysis
Continuous data in tables are presented as the median
and interquartile range (25th to 75th percentile), and
dichotomous data as n (%). Continuous data presented in
figures are depicted as the mean ± standard error of the
mean. Differences in patient characteristics between
study groups were compared using Pearson’s chi-square
test for dichotomous variables, with Fisher’s correction
when appropriate, and using the independent-sample t
test or Mann-Whitney U test for continuous data
depending on the Gaussian distribution (checked using
histograms and normal Q-Q plots). Continuous data
with multiple timepoints were analyzed using repeated
one-way analysis of variance with Bonferroni post-hoc
correction or the Kruskall-Wallis test with Dunn’s post-
hoc correction, depending on the Gaussian distribution.
Correlations were analyzed using Spearman correlation
(indicated as Rs) or Pearson correlation (r) depending on
the Gaussian distribution. Statistical calculations were
made using SPSS 15.0 for Windows (SPSS Inc.), and
Prism 4.03 for Windows (GraphPad Software Inc., San
Diego, CA, USA). P < 0.05 was considered to indicate sta-
tistical significance.
Results
Thirty patients were prospectively studied. The median
age of the total patient group was 56 years and the major-
ity of patients was male (n = 25, 83.3%). Most patients had
been diagnosed with acute myeloid leukemia (n = 21, 70%)
and all patients were in a stable clinical phase of their dis-
ease. Eight patients (26.7%) were transfused with 1 pRBC
unit, and 22 patients (73.3%) with 2 pRBC units. Interest-
ingly, the increase in hemoglobin following transfusion
was similar in patients receiving 1 or 2 pRBC units: from
8.2 g/l to 9.7 g/l. Other baseline and pRBC unit character-
istics also did not statistically differ between the two
groups (Table 1).
Prolonged storage of pRBCs results in elevated fHb levels
and increased NO-consuming capacity of the storage
medium
In total, 52 pRBC units were administered. The mean sto-
rage duration of the pRBC units was 17.2 days (range 2 to
32 days; Figure 1A), which was similar to previous reports
[12]. Of all transfused units, 4 pRBC units (7.2%) were
younger than 1 week while 11 pRBC units (21.2%) had
been stored for 3 weeks or longer. To analyze the degree
of hemolysis within the pRBC during storage, we mea-
sured fHb concentrations in the storage medium of each
transfused unit. The mean fHb level of the storage med-
ium was 25.9 ± 2.2 μmol/l, with a peak level of 96.7 μmol/
l. Corresponding to previous reports [6,8], prolonged sto-
rage duration correlated with fHb concentrations within
the storage medium (r = 0.51, P < 0.001; Figure 1B). As
fHb is a potent NO scavenger, we hypothesized that fHb
concentrations within the storage medium would posi-
tively correlate with the level of NO consumption of the
storage medium. The NO consumption of the storage
medium averaged 76.0 μmol/l (range 8.6 to 175.1 μmol/l),
and was significantly correlated with fHb levels of the sto-
rage medium (r = 0.61, P = 0.002; Figure 1C) and with the
storage duration of the pRBCs (r = 0.62, P = 0.002; data
not shown).
Transfusion of 2 pRBC units results in increased plasma
fHb concentrations and NO consumption in patients
We next studied the effect of pRBC transfusion on plasma
fHb levels of the 30 recipients. Figure 2A depicts the base-
line and post-transfusion fHb concentrations, grouped
according to transfusion of 1 or 2 pRBC units. This subdi-
vision was made based on the notion that the latter group
would (theoretically) be subjected to a higher fHb load
and could thus display higher plasma fHb values after
transfusion. Baseline plasma fHb levels were statistically
similar between both groups. Interestingly, plasma fHb
values increased significantly in patients receiving 2 pRBC
units compared with baseline concentrations as early as
15 minutes after transfusion (from 2.6 ± 0.2 μmol/l to
4.6 ± 0.5 μmol/l, respectively; P < 0.001), and fHb levels
remained significantly enhanced compared with baseline
values throughout the next 2 hours. After 24 hours, fHb
levels had returned to pre-transfusion levels. Plasma fHb
concentrations in patients transfused with 1 pRBC unit
did not change significantly over time. Both the storage
duration and fHb concentrations of the storage medium
of the administered pRBCs were similar between patients
transfused with 1 or 2 pRBC units (P = 0.63 and P = 0.97,
respectively), and it is therefore less likely that these fac-
tors confound the observed differences in plasma fHb con-
centrations after transfusion between both groups.
Irradiation of stored pRBCs has been reported to increase
the storage lesion, especially membrane permeability [7].
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To exclude the potential confounding effect of pRBC irra-
diation on post-transfusion fHb concentrations in patients,
we compared fHb concentrations in the storage medium of
irradiated (n = 13) and nonirradiated (n = 39) pRBC units -
which were 23.6 ± 2.7 μmol/l and 26.7 ± 2.7 μmol/l, respec-
tively (P = 0.97). Moreover, post-transfusion fHb concen-
trations in plasma were not significantly different between
patients receiving irradiated blood products versus patients
receiving nonirradiated blood products (P > 0.05 on all
timepoints; data not shown).
NO consumption was subsequently measured in all
plasma samples of a randomly selected subgroup of 13
patients (Figure 2B). In line with the fHb data, the plasma
NO consumption rose significantly in patients receiving 2
pRBC units from 6.1 ± 1.5 μmol/l at baseline to 7.9 ± 1.3
μmol/l 15 minutes after transfusion (P = 0.03), remaining
elevated during the first hour after transfusion (P = 0.06).
Plasma NO consumption did not significantly change in
patients receiving 1 pRBC unit. Overall, NO consumption
in plasma correlated significantly with plasma fHb concen-
trations (Rs = 0.35, P = 0.003; data not shown).
Summarizing, the storage medium of stored pRBC
units is a potent NO-consuming medium as it contains
high levels of fHb. In line with this finding, plasma
levels of fHb and NO consumption increased signifi-
cantly in patients after transfusion of 2 pRBC units.
Pre-transfusion haptoglobin levels influence post-
transfusion plasma fHb concentrations in patients
The current debate concerning the assumed negative
effect of transfusion of pRBC units on patient outcome
mainly focuses on storage-related factors such as storage
duration. As we found a significant effect of storage dura-
tion on fHb levels and NO consumption within the sto-
rage medium, we studied whether the storage duration of
the pRBC units influenced post-transfusion fHb concen-
trations in vivo. Surprisingly, in our study the storage
duration of the pRBC unit did not correlate with post-
transfusion fHb concentrations or NO consumption in the
recipient, even after correction for the number of pRBCs
transfused and for fHb concentrations of the storage med-
ium (data not shown).
We next studied the effect of pRBC transfusion on
post-transfusion Hp concentrations in the recipient. As
Hp is the physiological scavenger protein for fHb, and
considering the significant increase of circulating fHb
Table 1 Patient and packed red blood cell unit characteristics
Patients receiving 1 pRBC unit (n = 8) Patients receiving 2 pRBC units (n = 22) P value
Patient characteristics
Age (years) 51.0 (23.0-61.0) 58.5 (43.5-68.0) 0.118
Male 87.5 (7) 81.8 (18) 1.000
Disease 0.530
Acute myeloid leukemia 75.0 (6) 68.2 (15)
Multiple myeloma 12.5 (1) -
Burkitt’s lymphoma - 4.5 (1)
Acute lymphoblastic leukemia - 4.5 (1)
Testis carcinoma 12.5 (1) -
Myeloid sarcoma - 4.5 (1)
Non-Hodgkin B-cell lymphoma - 9.1 (2)
Myelodysplastic lymphoma - 9.1 (2)
Pre-transfusion hemoglobin (g/dl) 8.2 (7.8-8.5) 8.2 (7.5-8.4) 0.383
Post-transfusion hemoglobin (g/dl) 9.7 (9.0-10.0) 9.7 (9.2-10.2) 0.459
Pre-transfusion plasma haptoglobin (g/l) 2.1 (1.3-3.8) 2.4 (1.5-2.8) 0.784
Pre-transfusion serum bilirubin (μmol/l) 16.8 (12.2-28.0) 15.0 (13.4-22.3) 0.872
Pre-transfusion serum AST (IU/l) 16.0 (14.0-44.0) 14.0 (11.0-21.0) 0.231
Pre-transfusion serum ALT (IU/l) 28.0 (17.0-50.0) 24.5 (14.8-35.3) 0.507
Pre-transfusion serum creatinine (mmol/l) 65.0 (57.0-75.0) 67.0 (58.3-85.5) 0.508
Packed red blood cell characteristics
Blood type 1.000
O 75.0 (6) 59.1 (13)
A 25.0 (2) 31.8 (7)
B - 9.1 (2)
AB - -
Rh-negative 62.5 (5) 59.1 (13) 1.000
Data presented as median (interquartile range, 25% to 75%) or percentage (n). pRBC, packed red blood cell. There were no significant changes between the
study groups for any of the variables shown.
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Figure 1 Packed red blood cell storage duration correlates with increased free hemoglobin and nitric oxide consumption. (A)
Histogram of storage duration for all transfused packed red blood cell (pRBC) units (n = 52). Mean storage duration was 17.2 days (range 2 to
32 days). (B) Correlation between storage duration and the free hemoglobin (fHb) concentrations of the storage medium (SM) for each pRBC
unit (n = 52). (C) Correlation between the fHb concentration and nitric oxide (NO) consumption within the SM in a random selection of 22
pRBC units. Black lines depict a nonlinear regression (exponential) curve.
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Figure 2 Transfusion of stored red blood cells significantly increases plasma free hemoglobin and nitric oxide consumption. (A) Course
of plasma free hemoglobin (fHb) in patients receiving 1 (white bars) or 2 (grey bars) packed red blood cell (pRBC) units from baseline levels
before blood transfusion (BT) to 15, 30, 60 and 120 minutes and 24 hours after BT. ***Significant changes of fHb levels within groups compared
with baseline fHb concentrations; P < 0.001. (B) Course of plasma nitric oxide (NO) consumption in a random selection of four patients
transfused with 1 pRBC unit and nine patients transfused with 2 pRBC units. *Significant differences of fHb levels within groups compared with
baseline fHb concentrations; P < 0.05.
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concentrations following transfusion of 2 pRBC units, we
expected decreased post-transfusion Hp levels in these
patients. However, Hp levels did not change significantly
after transfusion in patients receiving 1 pRBC unit or 2
pRBC units (Figure 3A).
We subsequently investigated whether pre-transfu-
sion Hp concentrations of the recipient influenced
post-transfusion fHb levels, as patients with low pre-
transfusion Hp levels may have a lower capacity to
clear fHb. To that end, we divided patients into three
groups based on their pre-transfusion plasma Hp level.
Eighteen patients (60%) displayed high pre-transfusion
Hp concentrations exceeding 1.9 g/l (upper normal
level). In contrast, three patients (10%) presented Hp
concentrations below 0.75 g/l. Post-transfusion fHb
concentrations showed a more pronounced increase
Figure 3 Post-transfusion plasma haptoglobin, and pre-transfusion haptoglobin impact on post-transfusion free hemoglobin and
nitric oxide consumption. (A) Change of plasma haptoglobin in patients receiving 1 (white bars) or 2 (grey bars) packed red blood cell (pRBC)
units from levels before blood transfusion (BT) to 15, 30, 60 and 120 minutes and 24 hours after BT. (B) Change of plasma free hemoglobin (fHb)
in patients with pre-transfusion haptoglobin plasma concentrations of 1.9 g/l or higher (white bars), between 0.75 and 1.9 g/l (light-grey bars), or
0.75 g/l or lower (dark-grey bars). Significant changes of fHb levels within groups compared with baseline (pre-transfusion) levels: *P < 0.05, **P
< 0.01, ***P < 0.001. Statistical differences between groups are indicated with black bars and according P values. NS, nonsignificant.
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from pre-transfusion levels in patients with the lowest
pre-transfusion Hp concentrations, compared with
patients with higher pre-transfusion Hp levels (P <
0.05; Figure 3B). Storage duration of the administered
pRBCs was similar between the three groups (P =
0.20), as was the mean number of pRBCs transfused (1
or 2 units, P = 0.85) and the mean fHb concentration
of the storage medium of the pRBC units (P = 0.53).
Furthermore, similar results were obtained when
patients receiving 1 or 2 pRBC units were analyzed
separately (data not shown). Unfortunately, the study
was not sufficiently powered to allow statistical analy-
sis of changes in post-transfusion plasma NO con-
sumption based on pre-transfusion Hp levels.
Discussion
The relation between transfusion of stored blood and
adverse outcome in patients is the subject of intense
debate. Although the development of functional and struc-
tural changes of the RBCs during storage is undisputed, it
remains controversial whether these changes carry any
clinical relevance. In recent years, several studies have
reported on the association between increased storage
duration of pRBCs (reflecting increased storage lesion)
and adverse outcome in trauma patients [22], septic
patients [13,23], the critically ill [24], and patients under-
going cardiac surgery [12,25]. In contrast, other investiga-
tors did not find such associations [14,15,26,27] The
development of hemolysis within the pRBC unit, with
release of the NO-scavenging protein fHb, may contribute
to the potential adverse relation between blood transfu-
sions and patient outcome [6].
This observational study investigated whether transfu-
sion of 1 or 2 stored pRBC units can result in increased
fHb concentrations and plasma NO consumption in the
recipient, and whether the increase in fHb levels is depen-
dent on the storage duration of the pRBC unit(s) or on
pre-transfusion recipient Hp levels. To this end, we stu-
died patients with a (hematological) malignancy in a stable
clinical phase of their disease as these patients could be
used as a model to study changes of plasma markers
before and after blood transfusions. First, we demonstrated
that prolonged storage significantly increased fHb concen-
trations and NO consumption within the pRBC storage
medium, which was in line with previous reports [8,28].
Second, we were able to demonstrate for the first time
that transfusion of 2 pRBC units significantly enhanced
plasma fHb concentrations and NO consumption in
patients. Third, the increase in post-transfusion fHb con-
centrations was most profound in patients with low pre-
transfusion Hp levels and was absent in patients with
highest Hp concentrations, irrespective of the number of
transfused pRBCs, the storage duration of the transfused
units, and the fHb concentrations within the storage
medium.
To date, studies reporting on the postulated adverse
effects of pRBC transfusion on patient outcome principally
focused on the contribution of pRBC-related factors, with
most attention being paid to the effect of storage duration.
We could not confirm a correlation between prolonged
storage and increased fHb levels (or increased NO con-
sumption) in our patients. Perhaps the uneven distribution
of the storage duration of the pRBC units and the rela-
tively small number of patients prevented us from finding
such a relation. Interestingly, however, we were able to
show an effect of pre-transfusion plasma Hp levels of the
recipient on changes of fHb following transfusion. High
plasma Hp levels prior to transfusion may improve the
physiological buffer capacity of the recipient to increased
plasma fHb concentrations. One could even hypothesize
that patients displaying increased Hp levels, such as
patients with profound systemic inflammation [29,30],
may be better protected against the potential adverse
effects of transfused fHb. In contrast, patients undergoing
(complex) cardiovascular surgery could be particularly
sensitive to transfusion-induced, fHb-mediated NO con-
sumption, as these patients frequently suffer Hp depletion
during surgery [31].
Our data may be of significant importance for patients
who require massive transfusion, such as critical care
patients, trauma patients, or patients undergoing major
aortic, cardiac, orthopedic, or gynecologic surgery [18,32].
Transfusion of multiple pRBC units may result in a signifi-
cant increase of plasma fHb levels and NO consumption.
Since plasma fHb concentrations of 6 μmol/l have been
shown to significantly impair the NO metabolism in vivo
[16], and levels over 10 μmol/l have been linked to the
development of renal injury and renal dysfunction [18],
excessive pRBC transfusion may potentially decrease
microcirculatory blood flow and contribute to organ com-
promise in these patients. Indeed, transfusion of pRBCs to
treat anemia during cardiopulmonary bypass has been
shown to be independently associated with increased urin-
ary markers of intestinal damage, renal injury, and dete-
rioration of kidney function compared with untreated
anemic patients [33,34]. A similar independent association
between pRBC transfusions and worse outcome was found
in anemic critically ill patients [35].
Although the presented associations between the num-
ber of transfused pRBC units and increased levels of fHb
and increased NO consumption do not imply causality,
the results of the current study elicit an interesting
dilemma regarding blood transfusions. On the one hand,
refraining from transfusing a (seriously) anemic patient
might further impair blood oxygen-carrying capacity and
tissue oxygenation, possibly causing tissue ischemia and
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organ failure. On the other hand, (massive) transfusion of
pRBC units, containing high amounts of fHb, could signifi-
cantly increase plasma fHb concentrations and NO
consumption in the recipient. This could hamper micro-
circulatory blood flow and may also ultimately lead to cel-
lular damage and organ failure. As the beneficial effects of
blood transfusions are undisputed, and safe alternatives to
blood storage are still lacking, efforts should be made to
minimize the unwanted effects of stored RBC transfusion.
If our results are confirmed by larger studies, the current
study provides opportunities for the development of pre-
ventive or treatment strategies.
Although we were able to demonstrate significant
results, the relatively small patient population prevented
correction for confounding variables such as disease
severity. Future studies are therefore essential to provide
additional insight into the (causal) relationships between
transfusion of stored blood, increased plasma fHb con-
centrations and plasma NO consumption, decreased
microcirculatory perfusion, and clinical outcome of the
recipient. Furthermore, we did not study the contribution
of RBC microvesicles, known to be released during
hemolysis and known to contain high concentrations of
fHb, on post-transfusion fHb concentrations in the reci-
pient [36]. In addition, the role of increased free (non-
transferrin-bound) iron levels was not studied [37].
Lastly, we acknowledge the fact that we extrapolate data
and results obtained in a specific patient group to other
patient settings. Notwithstanding, we consider that the
results of this pilot study provide an important additional
insight into the much-discussed relationship between
stored blood transfusion and adverse outcome in
patients, and therefore warrant additional investigation.
Conclusion
Our data indicate that transfusion of 2 stored RBC units
significantly increases plasma fHb concentrations and NO
consumption in the recipient. These data are of interest in
light of the ongoing debate and evaluation of the proposed
negative association between pRBC transfusions and
patient outcome, and may serve as a tool to improve
patient morbidity and mortality after transfusion.
Key messages
• Prolonged storage of pRBC units results in
increased fHb concentrations and NO consumption
within the storage medium.
• Transfusion of 2 pRBC units, in contrast to trans-
fusion of 1 pRBC unit, significantly increases circu-
lating fHb levels and plasma NO consumption in the
recipient, irrespective of storage duration.
• High pre-transfusion plasma Hp levels may be pro-
tective as they are inversely related to post-transfu-
sion fHb concentrations in the recipient.
Abbreviations
fHb: free hemoglobin; Hp: haptoglobin; NO: nitric oxide; PBS: phosphate-
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Acknowledgements
The authors wish to thank the nurses of the hematology and oncology
ward for their excellent technical assistance in sample collection.
Furthermore, the authors wish to thank the Annadal Foundation of the
Maastricht University Medical Center for financially supporting this study.
Author details
1Department of Surgery, Maastricht University Medical Center, P. Debyelaan
25, PO Box 5800, 6202 AZ Maastricht, the Netherlands. 2Nutrition and
Toxicology Research Institute Maastricht (NUTRIM), Maastricht University
Medical Center, P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, the
Netherlands. 3Central Diagnostic Laboratory, Maastricht University Medical
Center, P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, the Netherlands.
4Department of Pharmacology, Faculty of Medicine of Ribeirao Preto,
University of São Paulo, Av. Bandeirantes, 3900 Ribeirão Preto, São Paolo,
Brazil. 5Department of Hematology, Maastricht University Medical Center, P.
Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, the Netherlands.
6Cardiovascular Research Institute Maastricht (CARIM), Maastricht University
Medical Center, P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, the
Netherlands. 7European Vascular Center Maastricht-Aachen, the Netherlands-
Germany University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen,
Germany. 8Department of Vascular Surgery, University Hospital Aachen,
Pauwelsstraße 30, 52074 Aachen, Germany.
Authors’ contributions
ICVW designed and performed the research, collected, analyzed, and
interpreted data, and drafted and approved the manuscript. NCJdW
performed the research, interpreted data, and drafted and approved the
manuscript. JTCS performed the research, analyzed and interpreted data,
and drafted and approved the manuscript. EAMB interpreted data and
drafted and approved the manuscript. JET-S performed the research,
analyzed and interpreted data, and drafted and approved the manuscript.
MJJ drafted and approved the manuscript. WAB designed the study,
interpreted data, and drafted and approved the manuscript. All authors have
read and approved the manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 13 January 2012 Revised: 3 April 2012
Accepted: 25 May 2012 Published: 25 May 2012
References
1. Shaz BH, Hillyer CD: Is there transfusion-related acute renal injury?
Anesthesiology 2010, 113:1012-1013.
2. Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA,
Hebert PC, Anderson GL, Bard MR, Bromberg W, Chiu WC, Cipolle MD,
Clancy KD, Diebel L, Hoff WS, Hughes KM, Munshi I, Nayduch D, Sandhu R,
Yelon JA: Clinical practice guideline: red blood cell transfusion in adult
trauma and critical care. Crit Care Med 2009, 37:3124-3157.
3. Bennett-Guerrero E, Veldman TH, Doctor A, Telen MJ, Ortel TL, Reid TS,
Mulherin MA, Zhu H, Buck RD, Califf RM, McMahon TJ: Evolution of adverse
changes in stored RBCs. Proc Natl Acad Sci USA 2007, 104:17063-17068.
4. Wolfe LC: Oxidative injuries to the red cell membrane during
conventional blood preservation. Semin Hematol 1989, 26:307-312.
5. Ho J, Sibbald WJ, Chin-Yee IH: Effects of storage on efficacy of red cell
transfusion: when is it not safe? Crit Care Med 2003, 31:S687-S697.
6. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C,
Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D,
Kim-Shapiro DB, Gladwin MT: Nitric oxide scavenging by red blood cell
microparticles and cell-free hemoglobin as a mechanism for the red cell
storage lesion. Circulation 2011, 26:465-476.
7. Zubair AC: Clinical impact of blood storage lesions. Am J Hematol 2010,
85:117-122.
8. Gladwin MT, Kim-Shapiro DB: Storage lesion in banked blood due to
hemolysis-dependent disruption of nitric oxide homeostasis. Curr Opin
Hematol 2009, 16:515-523.
Vermeulen Windsant et al. Critical Care 2012, 16:R95
http://ccforum.com/content/16/3/R95
Page 10 of 11
9. Hod EA, Spitalnik SL: Harmful effects of transfusion of older stored red
blood cells: iron and inflammation. Transfusion 2011, 51:881-885.
10. Lee JS, Gladwin MT: Bad blood: the risks of red cell storage. Nat Med
2010, 16:381-382.
11. Adamson JW: New blood, old blood, or no blood? N Engl J Med 2008,
358:1295-1296.
12. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T,
Blackstone EH: Duration of red-cell storage and complications after
cardiac surgery. N Engl J Med 2008, 358:1229-1239.
13. Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxygen
delivery in patients with sepsis. JAMA 1993, 269:3024-3029.
14. Edgren G, Kamper-Jorgensen M, Eloranta S, Rostgaard K, Custer B, Ullum H,
Murphy EL, Busch MP, Reilly M, Melbye M, Hjalgrim H, Nyren O: Duration of
red blood cell storage and survival of transfused patients. Transfusion
2010, 50:1185-1195.
15. Walsh TS, McArdle F, McLellan SA, Maciver C, Maginnis M, Prescott RJ,
McClelland DB: Does the storage time of transfused red blood cells
influence regional or global indexes of tissue oxygenation in anemic
critically ill patients? Crit Care Med 2004, 32:364-371.
16. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN,
Gladwin MT: Cell-free hemoglobin limits nitric oxide bioavailability in
sickle-cell disease. Nat Med 2002, 8:1383-1389.
17. Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, Banks SM, Schechter AN,
Natanson C, Gladwin MT, Solomon SB: Hemolysis-associated endothelial
dysfunction mediated by accelerated NO inactivation by
decompartmentalized oxyhemoglobin. J Clin Invest 2005, 115:3409-3417.
18. Vermeulen Windsant IC, Snoeijs MG, Hanssen SJ, Altintas S, Heijmans JH,
Koeppel TA, Schurink GW, Buurman WA, Jacobs MJ: Hemolysis is
associated with acute kidney injury during major aortic surgery. Kidney
Int 2010, 77:913-920.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130:461-470.
20. Cruz-Landeira A, Bal MJ, Lopez-Rivadulla M: Determination of
methemoglobin and total hemoglobin in toxicological studies by
derivative spectrophotometry. J Anal Toxicol 2002, 26:67-72.
21. Wang X, Tanus-Santos JE, Reiter CD, Dejam A, Shiva S, Smith RD, Hogg N,
Gladwin MT: Biological activity of nitric oxide in the plasmatic
compartment. Proc Natl Acad Sci USA 2004, 101:11477-11482.
22. Zallen G, Offner PJ, Moore EE, Blackwell J, Ciesla DJ, Gabriel J, Denny C,
Silliman CC: Age of transfused blood is an independent risk factor for
postinjury multiple organ failure. Am J Surg 1999, 178:570-572.
23. Purdy FR, Tweeddale MG, Merrick PM: Association of mortality with age of
blood transfused in septic ICU patients. Can J Anaesth 1997, 44:1256-1261.
24. Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC: Increased rate of
infection associated with transfusion of old blood after severe injury.
Arch Surg 2002, 137:711-717.
25. Ranucci M, Carlucci C, Isgro G, Boncilli A, De Benedetti D, De la Torre T,
Brozzi S, Frigiola A: Duration of red blood cell storage and outcomes in
pediatric cardiac surgery: an association found for pump prime blood.
Crit Care 2009, 13:R207.
26. van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A: Effects
of storage time of red blood cell transfusions on the prognosis of
coronary artery bypass graft patients. Transfusion 2006, 46:1712-1718.
27. Vamvakas EC, Carven JH: Length of storage of transfused red cells and
postoperative morbidity in patients undergoing coronary artery bypass
graft surgery. Transfusion 2000, 40:101-109.
28. Salzer U, Zhu R, Luten M, Isobe H, Pastushenko V, Perkmann T,
Hinterdorfer P, Bosman GJ: Vesicles generated during storage of red cells
are rich in the lipid raft marker stomatin. Transfusion 2008, 48:451-462.
29. Nielsen MJ, Moestrup SK: Receptor targeting of hemoglobin mediated by
the haptoglobins: roles beyond heme scavenging. Blood 2009,
114:764-771.
30. Oliviero S, Cortese R: The human haptoglobin gene promoter:
interleukin-6-responsive elements interact with a DNA-binding protein
induced by interleukin-6. EMBO J 1989, 8:1145-1151.
31. Tanaka K, Kanamori Y, Sato T, Kondo C, Katayama Y, Yada I, Yuasa H,
Kusagawa M: Administration of haptoglobin during cardiopulmonary
bypass surgery. ASAIO Trans 1991, 37:M482-M483.
32. Hanssen SJ, Derikx JP, Vermeulen Windsant IC, Heijmans JH, Koeppel TA,
Schurink GW, Buurman WA, Jacobs MJ: Visceral injury and systemic
inflammation in patients undergoing extracorporeal circulation during
aortic surgery. Ann Surg 2008, 248:117-125.
33. Habib RH, Zacharias A, Schwann TA, Riordan CJ, Engoren M, Durham SJ,
Shah A: Role of hemodilutional anemia and transfusion during
cardiopulmonary bypass in renal injury after coronary revascularization:
implications on operative outcome. Crit Care Med 2005, 33:1749-1756.
34. Huybregts RA, de Vroege R, Jansen EK, van Schijndel AW, Christiaans HM,
van Oeveren W: The association of hemodilution and transfusion of red
blood cells with biochemical markers of splanchnic and renal injury
during cardiopulmonary bypass. Anesth Analg 2009, 109:331-339.
35. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E,
MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: The CRIT Study: anemia
and blood transfusion in the critically ill - current clinical practice in the
United States. Crit Care Med 2004, 32:39-52.
36. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C,
Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D,
Kim-Shapiro DB, Gladwin MT: Nitric oxide scavenging by red blood cell
microparticles and cell-free hemoglobin as a mechanism for the red cell
storage lesion. Circulation 2011, 124:465-476.
37. Gordeuk VR, Sachdev V, Taylor JG, Gladwin MT, Kato G, Castro OL: Relative
systemic hypertension in patients with sickle cell disease is associated
with risk of pulmonary hypertension and renal insufficiency. Am J
Hematol 2008, 83:15-18.
doi:10.1186/cc11359
Cite this article as: Vermeulen Windsant et al.: Blood transfusions
increase circulating plasma free hemoglobin levels and plasma nitric
oxide consumption: a prospective observational pilot study. Critical Care
2012 16:R95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vermeulen Windsant et al. Critical Care 2012, 16:R95
http://ccforum.com/content/16/3/R95
Page 11 of 11
